Pacira Pharmaceuticals Inc. (PCRX) has moved higher as of late, but there could definitely be trouble on the horizon for this company. That is because PCRX is now in overbought territory with an RSI value of 76.7. Furthermore, estimates for the Pacira Pharmaceuticals Inc. have been coming down, pushing it to a Zacks Rank #4 (Sell). This suggests that investors may better off exiting this stock before it falls back to Earth.
PACIRA PHARMACEUTICALS INC (PCRX): Free Stock Analysis Report
Zacks Investment Research
- Finance Trading
- Health Care Industry